Has Paul Wylie received payments from drug or device companies?

Yes. Drug and device makers reported $53,930 in general payments to Paul Wylie across 60 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Paul Wylie did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Paul Wylie come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Paul Wylie

Psychiatry · Little Rock, ARNPI 1114003480

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $48,388 of the $53,930 with a category attached, or 89.7%. Idorsia Pharmaceuticals US Inc accounts for 94.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $37,482 and has fallen 99.9% since, to $21 in 2025. Among psychiatry clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$53,930in general payments, 2019–2025

Across 60 payments — averaging $898.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Idorsia Pharmaceuticals US Inc$51K
Modernatx, Inc.$1K
Merck$1K
Johnson & Johnson$123
GSK$63
Supernus Pharmaceuticals, Inc.$38
plus $21 from 1 others

$3,439,073in research payments, 2019–2025

Across 880 payments — averaging $3908.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$788K
Janssen Research & Development, LLC$637K
Novavax Inc$562K
Modernatx, Inc.$240K
Otsuka Pharmaceutical Development & Commercialization, Inc.$218K
Eli Lilly$196K
plus $798K from 9 others

What the payments were for

Speaking & faculty fees$48,38890%
Travel & lodging$3,1316%
Food & beverage$2,3544%
Education$580%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Idorsia Pharmaceuticals US Inc	41	$51,102
Modernatx, Inc.	4	$1,309
Merck	11	$1,274
Johnson & Johnson	1	$123
GSK	1	$63
Supernus Pharmaceuticals, Inc.	1	$38
AstraZeneca	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

QUVIVIQ$50,674
INVEGA SUSTENNA$123

How this compares

$53,930 in reported general payments places this provider in the 95th percentile of 235 psychiatry providers in Arkansas.

See all psychiatry providers in Arkansas →

Other psychiatry in Little Rock

Leslie SmithLittle Rock$766K
Tad TillemansLittle Rock$656K
Margaret WeissLittle Rock$29K
Duong NguyenLittle Rock$14K
Philip MizellLittle Rock$5K
Richard FlaniginLittle Rock$5K
Robert FarrellLittle Rock$4K
Pawel KuryloLittle Rock$4K
Gintaras AukstuolisLittle Rock$4K
Charles LewisLittle Rock$4K

See the full list for Arkansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →